RecruitingPhase 1NCT07719920

A Phase Ia/Ib Study of HW221043 in Participants With Advanced Solid Tumors

A Phase I Study Evaluating the Safety, Pharmacokinetics, and Efficacy of HW221043 Tablets in Participants With Advanced Solid Tumors

Sponsor

Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

Enrollment

99 participants

Start Date

Sep 10, 2026

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors

Summary

This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and preliminary efficacy of HW221043 tablets in participants with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and the dose expansion study (Phase Ib).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HW221043 Tablets for people with advanced solid tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.